(Q39336527)

English

The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models (English)

1 reference

Europe PubMed Central

11 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jennifer S Michaelson

1

1 reference

Europe PubMed Central

11 September 2017

Rebecca Kelly

2

1 reference

Europe PubMed Central

11 September 2017

Lu Yang

3

1 reference

Europe PubMed Central

11 September 2017

Xiamei Zhang

4

1 reference

Europe PubMed Central

11 September 2017

Kathleen Wortham

5

1 reference

Europe PubMed Central

11 September 2017

Ingrid B J K Joseph

6

1 reference

Europe PubMed Central

11 September 2017

publication date

6 June 2012

1 reference

Europe PubMed Central

11 September 2017

Cancer Biology and Therapy

1 reference

Europe PubMed Central

11 September 2017

13

1 reference

Europe PubMed Central

11 September 2017

9

1 reference

Europe PubMed Central

11 September 2017

812-821

1 reference

Europe PubMed Central

11 September 2017

Death receptor agonists as a targeted therapy for cancer

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Tweak induces mammary epithelial branching morphogenesis.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Development of an Fn14 agonistic antibody as an anti-tumor agent

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Multiple pathways of TWEAK-induced cell death

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

TWEAK can induce cell death via endogenous TNF and TNF receptor 1.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.20564

21 January 2018

Identifiers

10.4161/CBT.20564

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39336527&oldid=1820639265"